Mutagenetix

Phenotypic Mutation Search
(Enter search values into fields. Blank fields will be ignored.)

Gene Symbol
Gene Name
Allele
Institutional Source
Author
Chromosome
Type of Mutation
DNA Base Change (assembly)	⇒
Amino Acid Change	changed to
Mode of Inheritance
Phenotypic Category	Match selected phenotypes
Repository
Pedigree
Photo
Last Update	-

125-03 Response - decreased
125-03 Response - increased
30 min GTT hyperglycemic
30 min GTT hyperglycemic (male)
30 min GTT hyperoglycemic (female)
30 min GTT hypoglycemic
30 min GTT hypoglycemic (female)
30 min GTT hypoglycemic (male)
adenovirus infection of macrophages - decreased
adenovirus infection of macrophages - increased
adipose tissue
anemia
Anophthalmia
autoimmunity
B cells - decreased
B cells - increased
B:T cells - decreased
B:T cells - increased
B1 cells - decreased
B1 cells - increased
B1a cells - decreased
B1a cells - increased
B1a cells in B1 cells - decreased
B1a cells in B1 cells - increased
B1b cells - decreased
B1b cells - increased
B1b cells in B1 cells - decreased
B1b cells in B1 cells - increased
B2 cells - decreased
B2 cells - increased
B220 MFI in B cells - decreased
B220 MFI in B cells - increased
behavior/neurological
Blood pressure defect: decrease in DBP average
Blood pressure defect: decrease in DBP Day 1
Blood pressure defect: decrease in DBP Day 2
Blood pressure defect: decrease in DBP Day 3
Blood pressure defect: decrease in HR average
Blood pressure defect: decrease in HR day 1
Blood pressure defect: decrease in HR day 2
Blood pressure defect: decrease in HR day 3
Blood pressure defect: decrease in MBP average
Blood pressure defect: decrease in MBP Day 1
Blood pressure defect: decrease in MBP Day 2
Blood pressure defect: decrease in MBP Day 3
Blood pressure defect: decrease in SBP average
Blood pressure defect: decrease in SBP day 1
Blood pressure defect: decrease in SBP day 2
Blood pressure defect: decrease in SBP day 3
Blood pressure defect: increase in DBP average
Blood pressure defect: increase in DBP Day 1
Blood pressure defect: increase in DBP Day 2
Blood pressure defect: increase in DBP Day 3
Blood pressure defect: increase in HR average
Blood pressure defect: increase in HR day 1
Blood pressure defect: increase in HR day 2
Blood pressure defect: increase in HR day 3
Blood pressure defect: increase in MBP average
Blood pressure defect: increase in MBP Day 1
Blood pressure defect: increase in MBP Day 2
Blood pressure defect: increase in MBP Day 3
Blood pressure defect: increase in SBP average
Blood pressure defect: increase in SBP Day 1
Blood pressure defect: increase in SBP day 2
Blood pressure defect: increase in SBP day 3
Body Weight - decreased
Body Weight - increased
Body Weight (BP Female) - decreased
Body Weight (BP Female) - increased
Body Weight (BP Male) - decreased
Body Weight (BP Male) - increased
Body Weight (BP) - decreased
Body Weight (BP) - increased
Body Weight (DSS Female) - decreased
Body Weight (DSS Female) - increased
Body Weight (DSS Male) - decreased
Body Weight (DSS Male) - increased
Body Weight (DSS) - decreased
Body Weight (DSS) - increased
Body Weight (Female) - decreased
Body Weight (Female) - increased
Body Weight (HFD, 0 weeks) - decreased
Body Weight (HFD, 0 weeks) - increased
Body Weight (HFD, 2 weeks) - decreased
Body Weight (HFD, 2 weeks) - increased
Body Weight (HFD, 4 weeks) - decreased
Body Weight (HFD, 4 weeks) - increased
Body Weight (Male) - decreased
Body Weight (Male) - increased
Bone: Fat Mass - decreased
Bone: Fat Mass - increased
Bone: Fat Mass (female) - decreased
Bone: Fat Mass (female) - increased
Bone: Fat Mass (male) - decreased
Bone: Fat Mass (male) - increased
Bone: Femur BMC - decreased
Bone: Femur BMC - increased
Bone: Femur BMC (female) - decreased
Bone: Femur BMC (female) - increased
Bone: Femur BMC (male) - decreased
Bone: Femur BMC (male) - increased
Bone: Femur BMD - decreased
Bone: Femur BMD - increased
Bone: Femur BMD (female) - decreased
Bone: Femur BMD (female) - increased
Bone: Femur BMD (male) - decreased
Bone: Femur BMD (male) - increased
Bone: Femur Length - decreased
Bone: Femur Length - increased
Bone: Femur Length (female) - decreased
Bone: Femur Length (female) - increased
Bone: Femur Length (male) - decreased
Bone: Femur Length (male) - increased
Bone: Fore Hip Distance - decreased
Bone: Fore Hip Distance - increased
Bone: Fore Hip Distance (female) - decreased
Bone: Fore Hip Distance (female) - increased
Bone: Fore Hip Distance (male) - decreased
Bone: Fore Hip Distance (male) - increased
Bone: Gross Limb
Bone: Hind Hip Distance (female) - decreased
Bone: Hind Hip Distance (female) - increased
Bone: Hind Hip Distance (male) - decreased
Bone: Hind Hip Distance (male) - increased
Bone: Kinked Tail
Bone: Kyphosis
Bone: Lean Fat Ratio - decreased
Bone: Lean Fat Ratio - increased
Bone: Lean Fat Ratio (female) - decreased
Bone: Lean Fat Ratio (female) - increased
Bone: Lean Fat Ratio (male) - decreased
Bone: Lean Fat Ratio (male) - increased
Bone: Lean Mass - decreased
Bone: Lean Mass - increased
Bone: Lean Mass (female) - decreased
Bone: Lean Mass (female) - increased
Bone: Lean Mass (male) - decreased
Bone: Lean Mass (male) - increased
Bone: Limb Anomaly
Bone: Pelvic Anomaly
Bone: Pelvis Length - decreased
Bone: Pelvis Length - increased
Bone: Pelvis Length (female) - decreased
Bone: Pelvis Length (female) - increased
Bone: Pelvis Length (male) - decreased
Bone: Pelvis Length (male) - increased
Bone: Scoliosis
Bone: Short Tail
Bone: Tibia BMC - decreased
Bone: Tibia BMC - increased
Bone: Tibia BMC (female) - decreased
Bone: Tibia BMC (female) - increased
Bone: Tibia BMC (male) - decreased
Bone: Tibia BMC (male) - increased
Bone: Tibia BMD - decreased
Bone: Tibia BMD - increased
Bone: Tibia BMD (female) - decreased
Bone: Tibia BMD (female) - increased
Bone: Tibia BMD (male) - decreased
Bone: Tibia BMD (male) - increased
Bone: Tibia Length - decreased
Bone: Tibia Length - increased
Bone: Tibia Length (female) - decreased
Bone: Tibia Length (female) - increased
Bone: Tibia Length (male) - decreased
Bone: Tibia Length (male) - increased
Bone: Tibia Ratio (female) - decreased
Bone: Tibia Ratio (female) - increased
Bone: Tibia Ratio (male) - decreased
Bone: Tibia Ratio (male) - increased
Bone: Vertebral Anomaly
cardiovascular system
CD11b+ DCs in CD11c+ cells - decreased
CD11b+ DCs in CD11c+ cells - increased
CD11c+ DCs - decreased
CD11c+ DCs - increased
CD4:CD8 - decreased
CD4:CD8 - increased
CD4+ T cells - decreased
CD4+ T cells - increased
CD4+ T cells in CD3+ T cells - decreased
CD4+ T cells in CD3+ T cells - increased
CD44 MFI in CD4 - decreased
CD44 MFI in CD4 - increased
CD44 MFI in CD8 - decreased
CD44 MFI in CD8 - increased
CD44 MFI in T cells - decreased
CD44 MFI in T cells - increased
CD44+ CD4 T cells - decreased
CD44+ CD4 T cells - increased
CD44+ CD8 T cells - decreased
CD44+ CD8 T cells - increased
CD44+ T cells - decreased
CD44+ T cells - increased
CD8 response - decreased
CD8+ T cells - decreased
CD8+ T cells - increased
CD8+ T cells in CD3+ T cells - decreased
CD8+ T cells in CD3+ T cells - increased
CD8a+ DCs in CD11c+ cells - decreased
CD8a+ DCs in CD11c+ cells - increased
cellular phenotype
central memory CD4 T cells in CD4 T cells - decreased
central memory CD4 T cells in CD4 T cells - increased
central memory CD8 T cells in CD8 T cells - decreased
central memory CD8 T cells in CD8 T cells - increased
Circadian defect: decrease in body weight over wheel testing
Circadian defect: decrease in circadian active phase duration
Circadian defect: decrease in circadian blood glucose
Circadian defect: decrease in circadian phase angle intercept
Circadian defect: decrease in circadian power FFT
Circadian defect: decrease in circadian tau activity onset
Circadian defect: decrease in circadian tau DD by eye
Circadian defect: decrease in final body weight
Circadian defect: decrease in tau chi squared periodogram
Circadian defect: decreased wheel revs/24H
Circadian defect: increase in body weight over wheel testing
Circadian defect: increase in circadian active phase duration
Circadian defect: increase in circadian blood glucose
Circadian defect: increase in circadian phase angle intercept
Circadian defect: increase in circadian power FFT
Circadian defect: increase in circadian tau activity onset
Circadian defect: increase in circadian tau DD by eye
Circadian defect: increase in final body weight
Circadian defect: increase in tau chi squared periodogram
Circadian defect: increase in wheel revs/24H
Circadian rhythm
craniofacial
CTL killing - decreased
CTL killing - increased
CTL killing dominant epitope - decreased
CTL killing dominant epitope - increased
CTL killing subdominant epitope - decreased
CTL killing subdominant epitope - increased
defect in 125-03 response
digestive/alimentary
dsDNA Antibody - decreased
dsDNA Antibody - increased
dsDNA induced type I IFN production - decreased
dsDNA induced type I IFN production - increased
DSS: resistant
DSS: resistant day 10
DSS: resistant day 7
DSS: sensitive
DSS: sensitive day 10
DSS: sensitive day 7
effector memory CD4 T cells in CD4 T cells - decreased
effector memory CD4 T cells in CD4 T cells - increased
effector memory CD8 T cells in CD8 T cells - decreased
effector memory CD8 T cells in CD8 T cells - increased
effector T cells - decreased
effector T cells - increased
embryogenesis
endocrine/exocrine gland
extracellular cGAMP: high response
extracellular cGAMP: low response
eye: cataract
eye: chorioretinal lesions
eye: corneal opacity
eye: decrease in BM to ELM thickness
eye: decrease in BM to ILM thickness
eye: decrease in ILM to ONL thickness
eye: decrease in ONL thickness
eye: fundus spots
eye: increase in BM to ELM thickness
eye: increase in BM to ILM thickness
eye: increase in ILM to ONL thickness
eye: increase in ONL thickness
eye: iris anomaly
eye: keratouveitis
eye: optic nerve anomaly
eye: retinal cystic atrophy
eye: retinal detachment
eye: retinal vascular anomaly
eye: vitreoretinal development anomaly (PHPV)
fasting hyperglycemia
fasting hyperglycemia (female)
fasting hyperglycemia (male)
fasting hyperinsulinemia
fasting hyperinsulinemia (female)
fasting hyperinsulinemia (male)
fasting hypoglycemia
fasting hypoglycemia (female)
fasting hypoglycemia (male)
fasting hypoinsulinemia
fasting hypoinsulinemia (female)
fasting hypoinsulinemia (male)
Free Fatty Acid (HFD, 2h refeeding) - decreased
Free Fatty Acid (HFD, 2h refeeding) - increased
Free Fatty Acid (HFD, fasting) - decreased
Free Fatty Acid (HFD, fasting) - increased
Free Fatty Acid change (HFD, 2h refeeding ratio) - decreased
Free Fatty Acid change (HFD, 2h refeeding ratio) - increased
Free Fatty Acid change (HFD, 2h refeeding value) - decreased
Free Fatty Acid change (HFD, 2h refeeding value) - increased
Glucose (HFD, 2h refeeding) - decreased
Glucose (HFD, 2h refeeding) - increased
Glucose (HFD, fasting) - decreased
Glucose (HFD, fasting) - increased
growth/size
hearing/vestibular/ear
hematopoietic competition - disadvantage
hematopoietic system
high insulin levels after 30-minute glucose challenge (female)
high insulin levels after 30-minute glucose challenge (male)
high insulin levels after a 30-minute glucose challenge
homeostasis/metabolism
hypersensitivity to TLR CpGODN + IFNg
hyposensitivity to TLR CpGODN + IFNg
IgA response to 2nd OVA/Alum Challenge (day 7) - decreased
IgA response to 2nd OVA/Alum Challenge (day 7) - increased
IgD MFI in B cells - decreased
IgD MFI in B cells - increased
IgD+ B cells - decreased
IgD+ B cells - increased
IgE response to a Cysteine Protease (Papain) - decreased
IgE response to a Cysteine Protease (Papain) - increased
IgG1 response to a Cysteine Protease (Papain) - decreased
IgG1 response to a Cysteine Protease (Papain) - increased
IgM MFI in B cells - decreased
IgM MFI in B cells - increased
IgM+ B cells - decreased
IgM+ B cells - increased
immune system
impaired response to dsDNA- type I IFN production by macrophages
inflammatory bowel disease phenotype
influenza proliferation in macrophages - decreased
influenza proliferation in macrophages - increased
influenza resistance
innate fear - decreased
innate fear - increased
Insulin (HFD, 2h refeeding) - decreased
Insulin (HFD, 2h refeeding) - increased
Insulin (HFD, fasting) - decreased
Insulin (HFD, fasting) - increased
iron deficiency
iron excess
LCMV clone 13 resistance
lethality-embryonic/perinatal
lethality-postnatal
life span-post-weaning/aging
limbs/digits/tail phenotype
Liver Triglyceride (HFD) - decreased
Liver Triglyceride (HFD) - increased
liver/biliary system
low insulin levels after a 30-minute glucose challenge
LPS-induced Necroptosis - decreased
LPS-induced Necroptosis - increased
Macrophage necroptosis: high
Macrophage necroptosis: low
macrophages - decreased
macrophages - increased
MCMV proliferation in macrophages - decreased
MCMV proliferation in macrophages - increased
MCMV resistance
MCMV susceptibility
memory T cells - decreased
memory T cells - increased
MTT Value of PECs - decreased
MTT Value of PECs - increased
muscle
naive CD4 T cells in CD4 T cells - decreased
naive CD4 T cells in CD4 T cells - increased
naive CD8 T cells in CD8 T cells - decreased
naive CD8 T cells in CD8 T cells - increased
naive T cells - decreased
naive T cells - increased
NALP3 inflammasome signaling defect
nervous system
neutrophils - decreased
neutrophils - increased
NK cell response - decreased
NK cells - decreased
NK cells - increased
NK killing - decreased
NK killing - increased
NK T cells - decreased
NK T cells - increased
Nlrc4 inflammasome: high response
Nlrc4 inflammasome: low response
NLRP3 inflammasome: high response
NLRP3 inflammasome: low response
no phenotypic analysis
normal phenotype
Novelty: decrease in 20min activity
Novelty: decrease in familiar side activity
Novelty: decrease in familiar side time
Novelty: decrease in novel side activity
Novelty: decrease in novel side time
Novelty: decrease in preference percentage
Novelty: decrease in preference score
Novelty: decrease in total activity
Novelty: increase in 20min activity
Novelty: increase in familiar side activity
Novelty: increase in familiar side time
Novelty: increase in novel side activity
Novelty: increase in novel side time
Novelty: increase in preference percentage
Novelty: increase in preference score
Novelty: increase in total activity
other phenotype
OVA-specific IgE - decreased
OVA-specific IgE - increased
OVA-specific IgE after 2nd OVA/Alum - decreased
OVA-specific IgE after 2nd OVA/Alum - increased
PD-1 Ab treated melanoma (day 20, no tumor)
PD-1 Ab treated melanoma (day 20, no tumor, female)
PD-1 Ab treated melanoma (day 20, no tumor, male)
PD-1 Ab treated melanoma associated body weight gain (g) - decreased
PD-1 Ab treated melanoma associated body weight gain (g) - increased
PD-1 Ab treated melanoma body weight gain (%) - decreased
PD-1 Ab treated melanoma body weight gain (%) - increased
PD-1 Ab treated melanoma body weight gain (%) normalized to tumor weight - decreased
PD-1 Ab treated melanoma body weight gain (%) normalized to tumor weight - increased
PD-1 Ab treated melanoma body weight gain (%, female) - decreased
PD-1 Ab treated melanoma body weight gain (%, female) - increased
PD-1 Ab treated melanoma body weight gain (%, female) normalized to tumor weight - decreased
PD-1 Ab treated melanoma body weight gain (%, female) normalized to tumor weight - increased
PD-1 Ab treated melanoma body weight gain (%, male) - decreased
PD-1 Ab treated melanoma body weight gain (%, male) - increased
PD-1 Ab treated melanoma body weight gain (%, male) normalized to tumor weight - decreased
PD-1 Ab treated melanoma body weight gain (%, male) normalized to tumor weight - increased
PD-1 Ab treated melanoma body weight gain (g) normalized to tumor weight - decreased
PD-1 Ab treated melanoma body weight gain (g) normalized to tumor weight - increased
PD-1 Ab treated melanoma body weight gain (g, female) - decreased
PD-1 Ab treated melanoma body weight gain (g, female) - increased
PD-1 Ab treated melanoma body weight gain (g, female) normalized to tumor weight - decreased
PD-1 Ab treated melanoma body weight gain (g, female) normalized to tumor weight - increased
PD-1 Ab treated melanoma body weight gain (g, male) - decreased
PD-1 Ab treated melanoma body weight gain (g, male) - increased
PD-1 Ab treated melanoma body weight gain (g, male) normalized to tumor weight - decreased
PD-1 Ab treated melanoma body weight gain (g, male) normalized to tumor weight - increased
PD-1 Ab treated melanoma dead or alive
PD-1 Ab treated melanoma dead or alive (female)
PD-1 Ab treated melanoma dead or alive (male)
PD-1 Ab treated melanoma tumor volume (day 13) - decreased
PD-1 Ab treated melanoma tumor volume (day 13) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead and IM injection, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead and IM injection, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead and IM injection, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead and IM injection, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead and IM injection, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead and IM injection, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac sick or found dead, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 13, early sac, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, early sac, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 13, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, female) - increased
PD-1 Ab treated melanoma tumor volume (day 13, IM injection, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, IM injection, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 13, IM injection, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, IM injection, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 13, IM injection, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, IM injection, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 13, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, male) - increased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, early sac, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, early sac, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, early sac, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, early sac, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, early sac, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, early sac, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 13, no tumor, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 20) - decreased
PD-1 Ab treated melanoma tumor volume (day 20) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead and IM injection, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead and IM injection, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead and IM injection, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead and IM injection, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead and IM injection, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead and IM injection, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac sick or found dead, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 20, early sac, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, early sac, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 20, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, female) - increased
PD-1 Ab treated melanoma tumor volume (day 20, IM injection, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, IM injection, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 20, IM injection, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, IM injection, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 20, IM injection, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, IM injection, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 20, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, male) - increased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, early sac, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, early sac, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, early sac, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, early sac, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, early sac, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, early sac, trimmed, male) - increased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, trimmed) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, trimmed) - increased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, trimmed, female) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, trimmed, female) - increased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, trimmed, male) - decreased
PD-1 Ab treated melanoma tumor volume (day 20, no tumor, trimmed, male) - increased
pDCs in CD11c+ cells - decreased
pDCs in CD11c+ cells - increased
Pfizer: decrease in 30 Min Glucose Residual
Pfizer: decrease in 30 Min glucose residual (female)
Pfizer: decrease in 30 Min glucose residual (male)
Pfizer: decrease in DyMA Residual
Pfizer: decrease in DyMA-IR
Pfizer: decrease in fasting glucose residual
Pfizer: decrease in fasting glucose residual (female)
Pfizer: decrease in fasting glucose residual (male)
Pfizer: decrease in HOMA Residual
Pfizer: decrease in HOMA residual (female)
Pfizer: decrease in HOMA residual (male)
Pfizer: decrease in HOMA-IR
Pfizer: increase in 30 Min Glucose Residual
Pfizer: increase in 30 Min glucose residual (female)
Pfizer: increase in 30 Min glucose residual (male)
Pfizer: increase in DyMA Residual
Pfizer: increase in DyMA-IR
Pfizer: increase in fasting glucose residual
Pfizer: increase in fasting glucose residual (female)
Pfizer: increase in fasting glucose residual (male)
Pfizer: increase in HOMA Residual
Pfizer: increase in HOMA residual (female)
Pfizer: increase in HOMA residual (male)
Pfizer: increase in HOMA-IR
phagocytosis in PECs - decreased
phagocytosis in PECs - increased
pigmentation
polycythemia
post-MCMV B cells - decreased
post-MCMV B cells - increased
post-MCMV B:T cells - decreased
post-MCMV B:T cells - increased
post-MCMV B1 cells - decreased
post-MCMV B1 cells - increased
post-MCMV B1a cells - decreased
post-MCMV B1a cells - increased
post-MCMV B1a cells in B1 cells - decreased
post-MCMV B1a cells in B1 cells - increased
post-MCMV B1b cells - decreased
post-MCMV B1b cells - increased
post-MCMV B1b cells in B1 cells - decreased
post-MCMV B1b cells in B1 cells - increased
post-MCMV B2 cells - decreased
post-MCMV B2 cells - increased
post-MCMV B220 MFI in B cells - decreased
post-MCMV B220 MFI in B cells - increased
post-MCMV CD11b+ DCs in CD11c+ cells - decreased
post-MCMV CD11b+ DCs in CD11c+ cells - increased
post-MCMV CD11c+ DCs - decreased
post-MCMV CD11c+ DCs - increased
post-MCMV CD4:CD8 - decreased
post-MCMV CD4:CD8 - increased
post-MCMV CD4+ T cells - decreased
post-MCMV CD4+ T cells - increased
post-MCMV CD4+ T cells in CD3+ T cells - decreased
post-MCMV CD4+ T cells in CD3+ T cells - increased
post-MCMV CD44 MFI in CD4 - decreased
post-MCMV CD44 MFI in CD4 - increased
post-MCMV CD44 MFI in CD8 - decreased
post-MCMV CD44 MFI in CD8 - increased
post-MCMV CD44 MFI in T cells - decreased
post-MCMV CD44 MFI in T cells - increased
post-MCMV CD44+ CD4 T cells - decreased
post-MCMV CD44+ CD4 T cells - increased
post-MCMV CD44+ CD8 T cells - decreased
post-MCMV CD44+ CD8 T cells - increased
post-MCMV CD44+ T cells - decreased
post-MCMV CD44+ T cells - increased
post-MCMV CD8 response - decreased
post-MCMV CD8 response - increased
post-MCMV CD8+ T cells - decreased
post-MCMV CD8+ T cells - increased
post-MCMV CD8+ T cells in CD3+ T cells - decreased
post-MCMV CD8+ T cells in CD3+ T cells - increased
post-MCMV CD8a+ DCs in CD11c+ cells - decreased
post-MCMV CD8a+ DCs in CD11c+ cells - increased
post-MCMV central memory CD4 T cells in CD4 T cells - decreased
post-MCMV central memory CD4 T cells in CD4 T cells - increased
post-MCMV central memory CD8 T cells in CD8 T cells - decreased
post-MCMV central memory CD8 T cells in CD8 T cells - increased
post-MCMV effector memory CD4 T cells in CD4 T cells - decreased
post-MCMV effector memory CD4 T cells in CD4 T cells - increased
post-MCMV effector memory CD8 T cells in CD8 T cells - decreased
post-MCMV effector memory CD8 T cells in CD8 T cells - increased
post-MCMV effector T cells - decreased
post-MCMV effector T cells - increased
post-MCMV IgD MFI in B cells - decreased
post-MCMV IgD MFI in B cells - increased
post-MCMV IgD+ B cells - decreased
post-MCMV IgD+ B cells - increased
post-MCMV IgM MFI in B cells - decreased
post-MCMV IgM MFI in B cells - increased
post-MCMV IgM+ B cells - decreased
post-MCMV IgM+ B cells - increased
post-MCMV macrophages - decreased
post-MCMV macrophages - increased
post-MCMV memory T cells - decreased
post-MCMV memory T cells - increased
post-MCMV naive CD4 T cells in CD4 T cells - decreased
post-MCMV naive CD4 T cells in CD4 T cells - increased
post-MCMV naive CD8 T cells in CD8 T cells - decreased
post-MCMV naive CD8 T cells in CD8 T cells - increased
post-MCMV naive T cells - decreased
post-MCMV naive T cells - increased
post-MCMV neutrophils - decreased
post-MCMV neutrophils - increased
post-MCMV NK cell response - decreased
post-MCMV NK cell response - increased
post-MCMV NK cells - decreased
post-MCMV NK cells - increased
post-MCMV NK T cells - decreased
post-MCMV NK T cells - increased
post-MCMV pDCs in CD11c+ cells - decreased
post-MCMV pDCs in CD11c+ cells - increased
post-MCMV T cells - decreased
post-MCMV T cells - increased
ratio of OVA-specific IgE over the total IgE - decreased
ratio of OVA-specific IgE over the total IgE - increased
renal/urinary system
reproductive system
resistance to B10-F16 melanoma - decreased
resistance to B10-F16 melanoma - increased
respiratory system
response to injected CpG DNA - decreased
Rotarod time - decreased
Rotarod time - increased
RVFV proliferation in macrophages - decreased
RVFV proliferation in macrophages - increased
RVFV susceptibility
secretory SlgA after 2nd OVA/Alum Challenge (day 7) - decreased
secretory SlgA after 2nd OVA/Alum Challenge (day 7) - increased
skeleton phenotype
skin/coat/nails
suppression of LPS hypersensitivity
T cells - decreased
T cells - increased
taste/olfaction
T-dependent humoral response defect- decreased antibody response to OVA+ alum immunization
T-dependent humoral response defect- decreased antibody response to rSFV
T-dependent humoral response defect- increased antibody response to OVA+ alum immunization
T-dependent humoral response defect- increased antibody response to rSFV
T-independent B cell response defect- decreased TNP-specific IgM to TNP-Ficoll immunization
T-independent B cell response defect- increased TNP-specific IgM to TNP-Ficoll immunization
TLR signaling defect: hypersensitivity to CpG
TLR signaling defect: hypersensitivity to CpG + IFNg
TLR signaling defect: hypersensitivity to LPS
TLR signaling defect: hypersensitivity to MALP2
TLR signaling defect: hypersensitivity to PAM3CSK4
TLR signaling defect: hypersensitivity to poly I:C
TLR signaling defect: hypersensitivity to poly I:C + IFNg
TLR signaling defect: hypersensitivity to R848
TLR signaling defect: hyposensitivity to CpG
TLR signaling defect: hyposensitivity to CpG + IFNg
TLR signaling defect: hyposensitivity to LPS
TLR signaling defect: hyposensitivity to MALP2
TLR signaling defect: hyposensitivity to PAM3CSK4
TLR signaling defect: hyposensitivity to poly I:C
TLR signaling defect: hyposensitivity to poly I:C + IFNg
TLR signaling defect: hyposensitivity to R848
TLR signaling defect: TNF production by macrophages
TLR signaling defect: type I IFN production by macrophages
TLR signaling defect: type I IFN production by pDC
Total Cholesterol - decreased
Total Cholesterol - increased
total IgE after 2nd OVA/Alum - decreased
total IgE after 2nd OVA/Alum - increased
Total IgE After 2nd OVA/Alum Challenge (day 7) - decreased
Total IgE After 2nd OVA/Alum Challenge (day 7) - increased
total IgE level - decreased
total IgE level - increased
touch/vibrissae
tumorigenesis
vision/eye